Does Tirzepatide Cause Hair Loss?

Yes, hair loss can occur during tirzepatide treatment, but the evidence points more strongly to telogen effluvium after substantial or rapid weight loss than to a proven direct effect on the hair follicle. The careful answer to "does tirzepatide cause hair loss?" is that the drug is associated with more reports of shedding than placebo in obesity trials, while those trials did not diagnose the cause in each participant.

That distinction matters. A trial can establish that hair loss happened more often during treatment without establishing whether the molecule, the weight change, reduced food intake, a nutrient deficiency, or another condition caused it.

Does tirzepatide cause hair loss in trials?

Hair loss was uncommon but consistently reported more often with tirzepatide than with placebo. Three pivotal placebo-controlled SURMOUNT trials provide the clearest numbers:

The current Zepbound prescribing information pools SURMOUNT-1 and SURMOUNT-2. Its rounded rates are 5% at 5 mg, 4% at 10 mg, and 5% at 15 mg, compared with 1% on placebo. It also reports a marked sex difference: 7.1% of women and 0.5% of men receiving tirzepatide reported hair loss, versus 1.3% of women and 0% of men receiving placebo.

Those percentages should not be minimized, but they also should not be inflated into a prediction for one person. They are adverse-event reports, not dermatologist-confirmed cases of telogen effluvium. The trials were not designed to discover why the shedding occurred. The numbers also come from the branded trial product, not from a trial of Promise's compounded formulation, so they do not establish a formulation-specific rate for it. Tirzepatide clinical trials covers the broader evidence base.

Why rapid weight loss is the leading explanation

Telogen effluvium is diffuse, non-scarring shedding that begins after a physiological stressor shifts more follicles from the active growth phase into the resting phase. Rapid weight loss and severe caloric restriction were recognized triggers long before GLP-1 medicines existed. The lag built into the hair cycle is why shedding can appear months after the relevant change.

The tirzepatide label says the hair-loss reactions in its trials were associated with weight reduction. Independent evidence points the same way without proving that every case has the same cause. A 2024 retrospective study of 140 people diagnosed with telogen effluvium associated with weight loss found mean weight loss of 15.2% at an average 3.54 kg per month. That study was not about tirzepatide, and its averages are not a threshold below which shedding cannot happen.

Reduced intake may contribute alongside the weight change. Persistent nausea, early fullness, or a highly restrictive diet can make adequate energy, protein, iron, and other nutrients harder to maintain. A 2026 systematic review of GLP-1 therapies and hair loss found that rapid weight loss emerged as a potential contributor and that telogen effluvium was one of the main identified patterns. It also concluded that larger prospective studies are still needed to establish causality and timing. A direct medication effect therefore remains possible; it simply has less direct support at present.

The typical tirzepatide hair-loss timeline

The timing of telogen effluvium follows the hair cycle, not the injection calendar. A standard dermatology review describes abrupt diffuse shedding roughly two to three months after a trigger. That means the relevant trigger may be a period of fast weight loss, poor intake, illness, surgery, major stress, or a medication change that happened well before hair began collecting in the brush.

This is a typical telogen-effluvium sequence, not a forecast for everyone using tirzepatide. Some people notice shedding earlier or later. The tirzepatide trials did not publish a reliable onset-to-recovery curve, and neither the trial data nor general telogen-effluvium literature can promise complete regrowth for an individual.

What a prescriber can adjust

A prescriber has more options than simply continuing the same plan or stopping treatment. The useful review covers four areas.

The rate of dose escalation. If weight is falling quickly or gastrointestinal effects are limiting intake, the prescriber can decide to hold an escalation or select a lower maintenance dose. The product label bases maintenance-dose selection on response and tolerability. The actual dose and timing belong to the prescriber; the tirzepatide dosage schedule explains how those decisions are usually made.

Nutrition and weight trajectory. A clinician can review the rate of loss, appetite, vomiting or diarrhea, and whether the current eating pattern supplies enough total energy and protein. Correcting an identified shortfall is different from recommending a shelf of hair supplements without testing.

Other causes. Depending on the history and examination, a clinician may check a complete blood count, ferritin and iron studies, thyroid function, or selected nutrients. Recent illness, pregnancy, surgery, major stress, hormonal changes, and other medications also belong in the timeline.

The diagnosis itself. Diffuse shedding with a normal-looking scalp fits telogen effluvium better than smooth bald patches, broken hairs, scalp inflammation, or a steadily widening part. A primary-care prescriber can refer to dermatology when the pattern is unclear or the shedding persists.

At Promise, a licensed provider reviews every request and not everyone qualifies. If tirzepatide is prescribed, that provider can reassess the benefit-risk balance and make dose decisions rather than leaving the patient to troubleshoot alone.

When shedding needs a closer look

Hair loss should not automatically be attributed to tirzepatide just because the dates overlap. Patchy loss, eyebrow or body-hair loss, scalp pain, redness, scale, scarring, or many short broken hairs does not follow the usual telogen-effluvium pattern. A steadily widening part may reflect pattern hair loss that rapid shedding has made more visible.

It is also worth contacting the prescriber when shedding is heavy enough to cause visible thinning, continues beyond six months, begins without meaningful weight change, or accompanies fatigue, weakness, feeling unusually cold, menstrual changes, or other new symptoms. These details can change the workup. Tirzepatide side effects separates routine tolerability issues from symptoms that need faster attention.

Stopping tirzepatide does not necessarily stop shedding immediately because follicles already shifted into the resting phase can shed weeks later. Any medication change should be made with the prescriber after considering the weight trajectory, nutrition, other possible causes, and the reason tirzepatide was prescribed.

The honest bottom line is narrow: tirzepatide treatment is associated with a low but measurable rate of hair-loss reports, especially among women in the obesity trials. Rapid weight loss and restricted intake make telogen effluvium the better-supported explanation, but current evidence cannot rule out a direct drug contribution or guarantee what happens next for a particular person.